Rebecca Harris
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rebecca Harris has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Indra Neil Guha
NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, United Kingdom
5 shared publications - Guruprasad Padur Aithal
Department of Hepatology Nottingham University Hospitals NHS Trust Nottingham UK
3 shared publications - Jane I. Grove
Nottingham Digestive Diseases Centre, Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, United Kingdom; NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, United Kingdom
2 shared publications Toby Delahooke
Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, UK
2 shared publicationsAlessandro Cucchetti
1 shared publicationAquiline Chivinge
Ambulatory Care Pathway Matron
1 shared publication
Latest Publications
- Open Access
- 28 March 2023
- Published by Elsevier in JHEP Reports
- Vol. 5 (6) , 100743
PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease
- 28 March 2023
- Published by Elsevier in JHEP Reports
- Vol. 5 (6) , 100743
Open AccessPRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease
- Open Access
- 19 May 2020
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 51 (11) , 1199-1200
Editorial: how widespread and serious is non‐alcoholic fatty liver disease in the real world?
LINKED CONTENTThis article is linked to Loomba et al papers. To view these articles, visit https://doi.org/10.1111/apt.15679 and https://doi.org/10.1111/apt.15694.
- 19 May 2020
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 51 (11) , 1199-1200
Open AccessEditorial: how widespread and serious is non‐alcoholic fatty liver disease in the real world?
LINKED CONTENTThis article is linked to Loomba et al papers. To view these articles, visit https://doi.org/10.1111/apt.15679 and https://doi.org/10.1111/apt.15694.
- 1 October 2019
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 17 (11) , 2330-2338.e1
Validation of a Model for Identification of Patients With Compensated Cirrhosis at High Risk of Decompensation
- 1 October 2019
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 17 (11) , 2330-2338.e1
Validation of a Model for Identification of Patients With Compensated Cirrhosis at High Risk of Decompensation
- Open Access
- 1 November 2018
- Published by Wiley in United European Gastroenterology Journal
- Vol. 6 (9) , 1372-1379
The XL probe: A luxury or a necessity? Risk stratification in an obese community cohort using transient elastography
Background: Transient elastography is a non‐invasive tool which can stratify patients at risk of chronic liver disease. However, a raised body mass index has been independently associated with a failed or unreliable examination.Objective: The purpose of this study was to analyse the performance of two probes (M/XL) on a portable transient elastography device within an obese community population.Method: The method involved a prospective study with recruitment from a primary care practice. Patients identified with a risk factor for chronic liver disease were invited to a community‐based risk stratification pathway for transient elastography readings with both probes. A threshold of ≥8.0 kPa defined elevated liver stiffness.Results: A total of 477 patients attended the pathway. Of the patients, 21% had no valid measurements with the M probe. There was a significant difference between the probes in the proportion achieving ≥10 valid readings (M versus XL probe: 66.2% versus 90.2%; p ≤ 0.001) and in their reliability (M versus XL probe: 77.4% versus 98.5%; p = 0.028). Unreliable readings with the M probe increased as the body mass index increased. The XL probe re‐stratified 5.2% of patients to have a normal reading.Conclusion: The XL probe on a portable device significantly improves the applicability of transient elastography within a community‐based risk stratification pathway.
- 1 November 2018
- Published by Wiley in United European Gastroenterology Journal
- Vol. 6 (9) , 1372-1379
Open AccessThe XL probe: A luxury or a necessity? Risk stratification in an obese community cohort using transient elastography
Background: Transient elastography is a non‐invasive tool which can stratify patients at risk of chronic liver disease. However, a raised body mass index has been independently associated with a failed or unreliable examination.Objective: The purpose of this study was to analyse the performance of two probes (M/XL) on a portable transient elastography device within an obese community population.Method: The method involved a prospective study with recruitment from a primary care practice. Patients identified with a risk factor for chronic liver disease were invited to a community‐based risk stratification pathway for transient elastography readings with both probes. A threshold of ≥8.0 kPa defined elevated liver stiffness.Results: A total of 477 patients attended the pathway. Of the patients, 21% had no valid measurements with the M probe. There was a significant difference between the probes in the proportion achieving ≥10 valid readings (M versus XL probe: 66.2% versus 90.2%; p ≤ 0.001) and in their reliability (M versus XL probe: 77.4% versus 98.5%; p = 0.028). Unreliable readings with the M probe increased as the body mass index increased. The XL probe re‐stratified 5.2% of patients to have a normal reading.Conclusion: The XL probe on a portable device significantly improves the applicability of transient elastography within a community‐based risk stratification pathway.
- 2 June 2018
- Published by Mark Allen Group in Gastrointestinal Nursing
- Vol. 16 (5) , S15-S22
Risk-stratified screening for chronic liver disease using vibration-controlled transient elastography (Fibroscan)
Chronic liver disease is a prevalent and growing cause of death in the UK. Liver disease is often related to lifestyle-associated risk factors, and it is typically characterised by progressive fibrosis, which is often asymptomatic until the advanced stages of cirrhosis. Half of cases are diagnosed on emergency admission for decompensation. Effective public screening is necessary, and it is possible with risk stratification and the right diagnostic modalities. Liver biopsy is excessively invasive and biochemical liver function tests (LFTs) often miss serious asymptomatic liver disease. However, vibration-controlled transient elastography (VCTE) is a non-invasive, low-cost and accurate technology for assessing liver fibrosis through liver stiffness measurement (LSM) and controlled attenuation parameter (CAP). The hepatology team at Nottingham University Hospital developed a community pathway that allows GPs to identify at-risk patients and refer them for VCTE. This pathway is now an established nurse-led service.
- 2 June 2018
- Published by Mark Allen Group in Gastrointestinal Nursing
- Vol. 16 (5) , S15-S22
Risk-stratified screening for chronic liver disease using vibration-controlled transient elastography (Fibroscan)
Chronic liver disease is a prevalent and growing cause of death in the UK. Liver disease is often related to lifestyle-associated risk factors, and it is typically characterised by progressive fibrosis, which is often asymptomatic until the advanced stages of cirrhosis. Half of cases are diagnosed on emergency admission for decompensation. Effective public screening is necessary, and it is possible with risk stratification and the right diagnostic modalities. Liver biopsy is excessively invasive and biochemical liver function tests (LFTs) often miss serious asymptomatic liver disease. However, vibration-controlled transient elastography (VCTE) is a non-invasive, low-cost and accurate technology for assessing liver fibrosis through liver stiffness measurement (LSM) and controlled attenuation parameter (CAP). The hepatology team at Nottingham University Hospital developed a community pathway that allows GPs to identify at-risk patients and refer them for VCTE. This pathway is now an established nurse-led service.
- 25 March 2018
- Published by Wiley in Liver International
- Vol. 38 (10) , 1832-1838
Analysis of genotyping for predicting liver injury marker, procollagen III in persons at risk of non‐alcoholic fatty liver disease
Background & Aims: Chronic liver disease presents a major global public health challenge. Stratification of asymptomatic, at‐risk patients in primary care using non‐invasive methods has the potential to address this by identifying those likely to progress. We, therefore, evaluated variant alleles at loci associated with non‐alcoholic fatty liver disease as genetic determinants of substantial liver injury in patients with disease risk factors.Methods: Levels of serum procollagen III (PIIINP), an established fibrosis and steatohepatitis marker, were determined in 467 people who had type 2 diabetes and/or BMI > 27.3 (identified from registration with general practitioners) in this observational cross‐sectional study. Patients were genotyped for characterised risk alleles in PNPLA3 (rs738409), GCKR (rs1260326) and TM6SF2 (rs58542926) and associations with PIIINP assessed.Results: The risk alleles in PNPLA3, GCKR or TM6SF2 were not found to be individually associated with the presence of a disease risk factor and were not significantly more common in patients with raised serum PIIINP. The prevalence of possession of both PNPLA3 and GCKR variant alleles combined was significantly higher in at‐risk patients with clinically significant liver disease indicated by serum PIIINP above 11 ng/mL (P = .014).Conclusions: Genotyping, therefore, has limited value for predicting severe liver disease in at‐risk individuals identified in a community setting.
- 25 March 2018
- Published by Wiley in Liver International
- Vol. 38 (10) , 1832-1838
Analysis of genotyping for predicting liver injury marker, procollagen III in persons at risk of non‐alcoholic fatty liver disease
Background & Aims: Chronic liver disease presents a major global public health challenge. Stratification of asymptomatic, at‐risk patients in primary care using non‐invasive methods has the potential to address this by identifying those likely to progress. We, therefore, evaluated variant alleles at loci associated with non‐alcoholic fatty liver disease as genetic determinants of substantial liver injury in patients with disease risk factors.Methods: Levels of serum procollagen III (PIIINP), an established fibrosis and steatohepatitis marker, were determined in 467 people who had type 2 diabetes and/or BMI > 27.3 (identified from registration with general practitioners) in this observational cross‐sectional study. Patients were genotyped for characterised risk alleles in PNPLA3 (rs738409), GCKR (rs1260326) and TM6SF2 (rs58542926) and associations with PIIINP assessed.Results: The risk alleles in PNPLA3, GCKR or TM6SF2 were not found to be individually associated with the presence of a disease risk factor and were not significantly more common in patients with raised serum PIIINP. The prevalence of possession of both PNPLA3 and GCKR variant alleles combined was significantly higher in at‐risk patients with clinically significant liver disease indicated by serum PIIINP above 11 ng/mL (P = .014).Conclusions: Genotyping, therefore, has limited value for predicting severe liver disease in at‐risk individuals identified in a community setting.